Chimera Bioengineering
Dr. Vlad Hogenhuis, MD, MBA has an extensive work experience spanning several companies and roles. Vlad currently serves as the Chief Executive Officer of Chimera Bioengineering, where they lead the mission of using next-generation CAR T therapeutics to reprogram life and ultimately end cancer.
In addition to their role at Chimera Bioengineering, Dr. Hogenhuis serves as a Member of the Board of Directors for Rezolute, Inc., IHP Therapeutics, and GATT Technologies BV.
Prior to their current positions, Dr. Hogenhuis served as the Chief Operating Officer of Ultragenyx Pharmaceutical Inc. from September 2018 to June 2020. Before that, they held senior positions at GlaxoSmithKline, including SVP and Global Franchise Head of Specialty Care, and SVP and Global Franchise Lead of Cardiovascular, Metabolic, and Neurosciences.
Dr. Hogenhuis also held various roles at Merck, including Senior VP and Managing Director, Senior VP and Chief Marketing Officer, and Senior VP and General Manager. Vlad was responsible for global commercial activities and the commercialization of late-stage developmental products in Neuroscience, Dermatology, and Ophthalmology.
Earlier in their career, Dr. Hogenhuis worked as an Associate at McKinsey & Company and served as a Naval Lieutenant in the Royal Dutch Navy.
Furthermore, Dr. Hogenhuis has been involved in industry organizations and served as a Member of the Board of Directors for Pharma.be.
Overall, Dr. Vlad Hogenhuis has a diverse and extensive background in the pharmaceutical industry, leadership, and board participation.
Vlad Hogenhuis, MD, MBA, holds a Doctor of Medicine (MD) degree from Leiden University, where they studied medicine from 1982 to 1990. Before pursuing medicine, they attended Bischoppelijk college and Pius XII, although no specific degree is mentioned for these institutions. In 1990, they joined Tufts University School of Medicine as a Fellow to specialize in Outcomes Research. Following this, from 1992 to 1994, Vlad Hogenhuis attended The Wharton School to earn a Master of Business Administration (MBA) degree with a focus on Marketing/Marketing Management.
This person is not in any teams
Chimera Bioengineering
They aspire to control the immune system. By the time a patient is sitting in front of an oncologist, cancer has evaded their immune system. Chimeric antigen receptor T-cells (CARs) are reprogrammed immune cells, hot-wired to circumvent immune-evasion. Clinical trials for CARs against liquid tumor cancers, like acute lymphoblastic leukemia andlymphoma, have shown transformative results for patients unresponsive to standard therapy.However, limited efficacy against solid tumor cancers, life-threatening toxicities, and limited persistence are impediments to these therapies making a wider impact on cancer patients.Chimera Bioengineering solves the challenges of CARs with drug-responsive gene regulators, which allow us to re-program the "software" of the immune system. They design CAR behavior that promises to minimize toxicity, maximize efficacy and extend persistence so that CARs can lead to cures.w